Incision-free prostate surgery: Verona as an international reference center
At the Azienda Ospedaliera Universitaria Integrata di Verona, urological surgery is evolving toward an increasingly micro-invasive model thanks to EchoLaser TPLA technology.
The growing international interest — with specialists from multiple countries attending live procedures — highlights the central role of the Verona center in clinical innovation and in advancing minimally invasive techniques worldwide.
A network of excellence
This achievement is the result of strong collaboration between clinical expertise and technology partners.
Our sincere recognition goes to the physicians involved, who are leading this important advancement in prostate surgery.
Special thanks to:
- Rocamed, global licensing partner
- Luca Lamberti, EchoLaser Italy representative
- Elio Pachera, Veneto regional representative
Technology and collaboration: driving progress
The synergy between healthcare professionals, industry, and international networks is now a key factor in accelerating the adoption of innovative technologies and improving patients’ quality of life.
Within this context, EchoLaser stands out as a solution that combines precision, minimally invasive treatment, and meaningful clinical outcomes, helping redefine the standards of urological surgery.
https://www.aovr.veneto.it/urologia-aoui-fa-scuola-intervento-alla-prostata-senza-incisioni
Urologia AOUI Verona, la chirurgia senza incisioni attira specialisti da tutto il mondo
EchoLaser Enters the EAU Guidelines: A Step Forward for Minimally Invasive Urology
An important milestone for innovation in urology: the latest guidelines from the European Association of Urology on the management of male lower urinary tract symptoms (LUTS) now recognize transperineal laser ablation (TPLA) among emerging ablative techniques.
This update sends a clear message: the demand for increasingly minimally invasive and targeted therapeutic solutions continues to grow, with the goal of improving patient quality of life while reducing procedural impact.
In this evolving landscape, EchoLaser stands out as an advanced technology, offering a precise, customizable, and image-guided approach for the treatment of conditions such as benign prostatic hyperplasia (BPH).
Inclusion in the EAU guidelines is not only a scientific recognition, but also a confirmation of the clinical value and future potential of laser ablation in the global urology field.
We will continue to support the medical community in developing effective, safe, and patient-centered solutions.
👉 Discover more in the official EAU guidelines:
https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts/chapter/disease-management
EchoLaser TPLA in Turin: treating prostate cancer while traveling to the Caribbean through virtual reality
At Molinette Hospital in Turin, the university urology department led by Prof. Paolo Gontero has marked a turning point in prostate cancer surgery: EchoLaser TPLA (Transperineal Laser Ablation). This focal therapy, performed by Marco Oderda and Alessandro Marquis, allows physicians to precisely target prostate tumors while preserving surrounding healthy tissue, thanks to ultra-thin laser fibers guided by advanced fusion imaging between ultrasound and MRI.
Another element of innovation? While awake under local anesthesia, the patient wears a virtual reality headset, being “transported” to tropical beaches, the Amazon rainforest, the Milky Way or underwater landscapes, accompanied by soothing sounds. Far from a mere distraction, this immersive approach serves as a psychological aid, helping to reduce stress and anxiety during surgery.
This combined approach – surgical precision and emotional comfort – represents a significant step toward a medicine increasingly focused on patient-centered care and quality of life after treatment.
For EchoLaser TPLA, it is a source of pride to contribute to a solution that not only treats cancer effectively but also restores patients’ serenity and dignity.
EchoLaser TPLA at the 12th National Academic Conference on Minimally Invasive Surgery in Aerospace (China)
Over 400 experts from 28 provinces attended the 12th National Academic Conference on Minimally Invasive Surgery in Aerospace. We are proud that, for the third consecutive year, our Chinese partner, Chenglai Pharmaceutical, was among the key players at this prestigious event.
A highlight was the lecture by Dr. Paolo Polverino (San Giuseppe Hospital, Empoli – Italy), who presented:
“EchoLaser Transperineal Prostate Laser Ablation (TPLA): Technical Overview.”
His clinical expertise and focus on cutting-edge innovations generated great interest and brought valuable contributions to the scientific discussions.
A special thank you to Dr. Paolo Polverino for sharing his knowledge and to Chenglai Pharmaceutical for their outstanding organizational support.
EchoLaser TPLA continues to be recognized as a reference technology in minimally invasive prostate laser ablation, advancing laser surgery worldwide.